Advertisement
Advertisement
U.S. markets close in 3 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ikena Oncology, Inc. (IKNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
4.5800+0.0800 (+1.78%)
As of 12:17PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
Previous Close4.5000
Open4.5900
Bid4.5800 x 1000
Ask4.6200 x 1000
Day's Range4.5000 - 4.8500
52 Week Range2.8300 - 17.6000
Volume24,346
Avg. Volume288,730
Market Cap174.921M
Beta (5Y Monthly)N/A
PE Ratio (TTM)5.15
EPS (TTM)0.8900
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IKNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ikena Oncology, Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    24 days agoMorningstar
View more
  • GlobeNewswire

    Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

    BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, will participate in a panel discussion at the William Blair Biotech Focus Conference, taking place Wednesday, July 13, 2022 in New York, NY. Management will also be conducting one-on-one investor meetings at the conference. Details on the panel ca

  • GlobeNewswire

    Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

    BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-930, the Company’s novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM). Fast Track designation granted by FDA facilitates the de

  • Simply Wall St.

    We Think Ikena Oncology (NASDAQ:IKNA) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

Advertisement
Advertisement